Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Non-Current Assets of $833.7 million for Q4 2025, up 113.24% on a QoQ basis from $391.0 million in Q4 2024, and up 113.24% year-over-year from $391.0 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Non-Current Assets data on file, last reported at $833.7 million in Q4 2025.

  • In Q4 2025, Non-Current Assets rose 113.24% year-over-year to $833.7 million; the TTM figure through Dec 2025 stood at $833.7 million (up 113.24% YoY), while the FY2025 annual figure was $833.7 million, up 125.17% from the prior year.
  • Non-Current Assets climbed to $833.7 million in Q4 2025, from $391.0 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $833.7 million in Q4 2025 and bottomed at $112.9 million in Q4 2023.
  • A 3-year average of $445.9 million and a median of $391.0 million in 2024 frame the typical range for Non-Current Assets.
  • Annual changes were most pronounced in 2024 — Non-Current Assets jumped 246.25% — and 2025, when it soared 113.24%.
  • Year by year, Non-Current Assets stood at $112.9 million in 2023, then jumped by 246.25% to $391.0 million in 2024, then soared by 113.24% to $833.7 million in 2025.
  • The last three Non-Current Assets figures came in at $833.7 million (Q4 2025), $391.0 million (Q4 2024), and $112.9 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 4.56 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 62,953.78
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 486.60 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 5.83 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 14.75 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 22.66 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 910.24 Mn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 833.71 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 833.71 Mn
Dec 31, 2024 390.98 Mn
Dec 31, 2023 112.92 Mn